Podcasts about genes

Is extra virgin olive oil really as healthy as people claim? Or has it become another nutrition trend surrounded by conflicting opinions?In this solo episode of Everyday Epigenetics: Raw. Real. Relatable., Susan Robbins explores the science behind one of the most researched foods in the world: extra virgin olive oil (EVOO). Drawing from years of reviewing DNA reports, biomarkers, epigenetic testing, and current research, Susan explains why EVOO continues to stand out as one of the few foods she consistently recommends across a wide range of clients. She also breaks down common myths about dietary fat, cooking with olive oil, cholesterol, and why personalized nutrition will always matter more than following the latest diet trend.Whether you're trying to support heart health, reduce inflammation, improve insulin sensitivity, or simply make more informed food choices, this episode will help you understand why food is more than fuel, it's information that influences how your body functions every single day.In this episode:Why extra virgin olive oil continues to stand out across genetics, biomarkers, and nutrition researchThe connection between EVOO, inflammation, insulin sensitivity, cardiovascular health, and healthy agingWhy personalized nutrition is more effective than following one popular dietThe truth about cooking with extra virgin olive oil and whether it really is stable when heatedHow your genes influence the way your body responds to different dietary fatsPractical tips for choosing a high-quality extra virgin olive oil and incorporating it into your daily routineIf you've ever wondered whether olive oil deserves its reputation as one of the healthiest foods you can eat, this episode offers a practical, science-backed perspective that may change the way you think about one simple ingredient.RESOURCES:Find all of Susan's Resources and links in the show notes: Oxidative Stress Episode: https://healthyawakening.co/2025/12/19/episode102/Cholesterol Episode: https://healthyawakening.co/2026/03/16/episode115/https://healthyawakening.co/2026/07/20/episode133/Connect with Susan: https://healthyawakening.co/Visit the website: healthyawakening.co/podcastFind listening links here: https://healthyawakening.co/linksP.S. Want reminders about episodes? Sign up for our newsletter, you can find the link on our podcast page! https://healthyawakening.co/podcast

Clic... la magia de Holly Wood se va deshaciendo.Imágenes en Acción es una parodia/homenaje a las películas clásicas de Hollywood y a los mitos de Cthulhu.

19 07 2026 01 Abc Rural Diógenes Davalos Zusa Ovino by ABC Color

God söndag, kalenderbitare!  Idag sänder BerntJournalen direkt från högkvarteret med en fullständigt maxad upplaga. Vi går till botten med den ekonomiska skandalen 'Down Under' som tvingat Ace Frehley Band att ställa in, och avslöjar detaljerna kring Tommy Thayers helt nya funkrock-projekt med en helsvensk rytmsektion. Dessutom reder vi ut varför Genes lyxmässa i Vegas plötsligt skjuts upp till nästa år och bjuder på ett historiskt bildscoop från 1973. Som om inte det vore nog: Vi avslöjar hur 90-årige smörsångar-ikonen Engelbert Humperdinck smugit in två KISS-klassiker på sin nya rockplatta, tipsar om sommarpremiären av Hot in the Shade och sätter på oss teknikglasögonen i Prylhörnan. Vi granskar bandets nya hörlurar och bjuder på en rykande färsk prisjakt som sparar dig tusenlappar direkt i plånboken.  Häll upp kaffet och spänn fast er – nu kör vi!

Detritus salva gente.Imágenes en Acción es una parodia/homenaje a las películas clásicas de Hollywood y a los mitos de Cthulhu.

En Holy Wood no hay sonido.Imágenes en Acción es una parodia/homenaje a las películas clásicas de Hollywood y a los mitos de Cthulhu.

Platicamos con el chef Juan Emilio Villaseñor sobre la nueva era de la Cocinoteca, que regreso a sus orígenes, el centro de la ciudad de León.

La Cosa no aguanta caídas.Imágenes en Acción es una parodia/homenaje a las películas clásicas de Hollywood y a los mitos de Cthulhu.

Gaspode y Laddie son dos auténticos héroes.Imágenes en Acción es una parodia/homenaje a las películas clásicas de Hollywood y a los mitos de Cthulhu.

This week on Back Issue Bloodbath, Andrew and Petula check out the strangest tale involving Spider-Man, Punisher, and Sabretooth: Designer Genes! The post Back Issue Bloodbath Episode 552: Spider-Man Punisher Sabretooth – Designer Genes appeared first on Geek Hard.

This week on Back Issue Bloodbath, Andrew and Petula check out the strangest tale involving Spider-Man, Punisher, and Sabretooth: Designer Genes! The post Back Issue Bloodbath Episode 552: Spider-Man Punisher Sabretooth – Designer Genes appeared first on Geek Hard.

Gaspode y Laddie son dos auténticos héroes.Imágenes en Acción es una parodia/homenaje a las películas clásicas de Hollywood y a los mitos de Cthulhu.

En nuestro Orígenes de hoy hablamos con Don Eusebio Cabrera, ganador de la Espiga de Oro por su trabajo de Coplas a San Benito Abad. También desde Gran Canaria hablamos con Suso Santana y destacamos los Honores y Distinciones que entrega la Asociación Cultural Entre Amigos; por otro lado Don Jaime Hamad del Grupo Folclórico Verode nos invita a las III Jornadas Culturales que organizan con Concierto, Talleres de Baile y Charla. Además hablamos con Carmen Ferrera de las Bodegas Ferrera en Arafo que se suman al Campus de Etnografía y Folclore que organiza Coros y Danzas de Ingenio y junto a ella el historiador Javier Cruz que nos hablará de las Mujeres Algueras. Y nos vamos al XII Baile de Magos Tagorosteros en Tacoronte el próximo fin de semana; todo en La Diez Capital Radio con Joam Walo "poniendo lo canario más de moda que nunca y apostando por lo nuestro" #origenes #programaorigenes #ladiezradio #capitalradiogc #joamwalo

Gaspode utiliza el viejo truco de la nariz fría.Imágenes en Acción es una parodia/homenaje a las películas clásicas de Hollywood y a los mitos de Cthulhu.

¿Qué es un gen y cómo podemos entender su funcionamiento? 04:44¿Es muy complejo estudiar el código genético? 11:56¿Cuál es la relación de los genes con la diabetes en la población mexicana? 18:22

Lord Vetinari se hace preguntas acerca de la popularidad.Imágenes en Acción es una parodia/homenaje a las películas clásicas de Hollywood y a los mitos de Cthulhu.

El misterio de las pirámides Existen indicios sólidos de que la Gran Pirámide de Guiza pudo haber funcionado como una central energética. ¿Podrían estas estructuras ocultar claves sobre el pasado de la humanidad?

¿Qué te pareció este episodio?Un libro y tres exposiciones aportan a esa identidad que tanto necesitamos.Lee el artículo aquí: https://jugo.pe/memoria-colectiva-peru-libro-exposiciones-identidad Al suscribirte a Jugo recibes nuestro contenido diariamente. Tienes la oportunidad de ser juguero por un día. Pero, sobre todo, patrocinas que nuestro contenido llegue gratuitamente a personas que lo necesitan. Contamos con tu apoyo para no desenchufar la licuadora.Suscríbete aquí. Haz clic aquí para seguirnos en TwitterHaz clic aquí para seguirnos en FacebookHaz clic aquí para seguirnos en Instagram

Los magos tienen que ir por detrás, que no llevan nunca dinero.Imágenes en Acción es una parodia/homenaje a las películas clásicas de Hollywood y a los mitos de Cthulhu.

What if your family patterns, addictions, fears and trauma are not the final word? In this episode, Brandon and team talk with Dr. Luman Wing about epigenetics, transgenerational sin, addiction, sanctification and how the gospel may reach even deeper into our embodied lives than most Christians have imagined.Dr. Lu's book: https://amzn.to/3QR8z3HWebsite: https://lumanwing.org

Ginger no se atreve a bajar del carro y enfrentarse con sus fans.Imágenes en Acción es una parodia/homenaje a las películas clásicas de Hollywood y a los mitos de Cthulhu.

50% da longevidade humana depende da influência genética?See omnystudio.com/listener for privacy information.

La silla del mago Pons es más un tanque de guerra que una silla de ruedas al uso.Imágenes en Acción es una parodia/homenaje a las películas clásicas de Hollywood y a los mitos de Cthulhu.

El programa 2900 de Radiogeek repasa las novedades tecnológicas más importantes del día: Apple fabricará chips inalámbricos "Hecho en Estados Unidos" con Broadcom; La próxima función de copia de seguridad automática en PC de Android excluye los dispositivos Samsung; Elon Musk dice que X te enviará mensajes directos cuando se corrijan las publicaciones con las que hayas interactuado; Meta acaba de dificultar la grabación secreta con sus anteojos inteligentes; Ahora cualquiera puede usar tus fotos de Instagram para crear imágenes con IA sobre ti; y por último Nintendo cerrará Mario Kart Tour el 30 de septiembre sin versión offline. Toda esta información la pueden encontrar desde nuestra web www.infosertec.com.ar o bien desde el canal de Telegram/Whastapp, o Instagram. Esperamos sus comentarios.

Dr Sira Karvinen - Exercise | Longevity | Genes | Twins  Sira Karvinen currently works at the Gerontology Research Center, University of Jyväskylä, Finland. She is a postdoctoral researcher in a EsmiRs-study - Risk of metabolic dysfunction in middle aged women: systemic and intracrine oestrogen and microRNAs as mediating factors. --- This podcast episode is sponsored by Fibion Inc. | The New Gold Standard for Sedentary Behaviour and Physical Activity Monitoring Learn more about Fibion: fibion.com/research --- Physical Activity Researcher Podcast have created a ‘Purchase Guide for Researchers: Accelerometer-based Activity Trackers'. You can download it from here. ---

Livia Lazzaro Rezende es una historiadora del diseño brasileña que reside en Australia. Nos cuenta en esta entrevista su paso de diseñadora a historiadora. Y sobre su investigación en América latina. A ella le interesa entender la evolución de las instituciones de diseño en relación a su contexto, y nos convoca a hacer una historia de manera más colaborativa y reconociendo el impacto de los legados coloniales. Esta entrevista es parte de las listas: Historia del diseño, Brasil y diseño, Australia y diseño, Investigación en diseño.  Un capítulo de su autoría se puede encontrar en este libro: Building/Object. A collective of design educators: InterDesigning. Recomendaciones_ ‘Routes to Design History'  by the Design History Society, here. O projeto de Zeina Maasri, Decolonizing the Page: A Forgotten Golden Age of Arabic Book Arts (1950s–80s).  The documentary film Art on the Streets (Harriet Atkinson, co-directed with Jane Dibblin, 2023), see trailer here.  Os trabalhos da aborígene Angie Abdilla e seu grupo ‘Old Ways, New'.

No pondré ante mis ojos cosa injusta (Salmo 101:3).Imágenes fuertes ~ Devocional de Jóvenes ~ 4 de julio 2026 ~ AD7Devocional----------------------------Code: ERDWDVOYYPYHAYX2BUSCA en Facebook el texto de la matutina:http://www.facebook.com/AD7Devocional/SIGUE en Instagram el post de la matutina y el versículo diario:http://www.instagram.com/AD7Devocional/VISITA nuestra pagina de internet:http://www.ad7devocional.comSUSCRIBE a YouTube, comparte y ve nuestros videos:http://www.youtube.com/AD7DevocionalESCUCHA a traves de Spotify:https://open.spotify.com/show/4VfzQUU2omzsrqITRsL6AhAutor: Milton Andrade (Andrade, Milton)Titulo: Inverso / DiferenteMatutina Para JóvenesDevoción Matutina Para JóvenesGracias a Ti por escucharnos, un abrazo AD7… Hasta la próxima!Este episodio incluye contenido generado por IA.

Ebook: https://drive.google.com/file/d/1AUsxg05dXkKFeAa64kC0u16XynnSx68o/view?usp=drive_link Episode Description: Every peptide conversation right now is about GLP-1 drugs, BPC-157, and TB-500. Nobody is talking about the one with 50 years of published research that your body is already making and losing as you age. GHK-Cu is a naturally occurring tripeptide that declines by 60% between the ages of 20 and 60. That decline tracks directly with the loss of skin elasticity, slower wound healing, thinning hair, reduced collagen production, and rising inflammation. In randomized controlled trials it has outperformed Rogaine for hair growth, shown a 55% reduction in visible wrinkles, and been documented to positively affect the expression of over 4,000 human genes. Dr. G calls it his favorite peptide, and his partner uses it on her face every day. In this episode, you will learn:  • How GHK-Cu works as a copper delivery vehicle at the cellular level, why it modulates gene expression across 31% of the human genome, and what that means for tissue repair, inflammation, and biological aging  • The head to head randomized controlled trial where GHK-Cu outperformed minoxidil for hair count, follicle size, and the active growth phase of the hair cycle  • Exactly what to look for when buying GHK-Cu cream, why the peptide is chemically fragile, what packaging and pH range to require, and the red flags that tell you to walk away from a product Timestamps: 0:00 - Intro 1:44 - What GHK-CU Actually Is and How It Was First Discovered in 1973 3:10 - Why a 60% Decline in GHK-CU Between Ages 20 and 60 Tracks Directly With Aging 4:40 - What Makes GHK-CU Different From Every Other Popular Peptide 6:00 - How It Stimulates Collagen, Elastin & the Extracellular Matrix 7:15 - The Human Trial Showing a 51% Increase in Collagen Density From Topical Application 8:00 - The 4,000 Genes GHK-CU Affects (And What the Broad Institute Found) 9:30 - Anti-Inflammatory Effects: Why This Matters for Biological Aging 10:30 - Wound Healing, Angiogenesis & Tissue Repair Across Skin, Bone, Gut and Liver 11:30 - The 2022 RCT: 55.7% Reduction in Visible Wrinkles After 12 Weeks 12:30 - Hair Growth: Outperforming Minoxidil in a Head-to-Head Randomized Trial 14:30 - Why the Lower Dose (50mg/ml) Outperformed the Higher Dose 15:30 - Safety Profile, Contraindications & the "Copper Uglies" Explained 17:00 - How to Buy GHK-CU: Concentration, Packaging, pH & What to Avoid Learn more about your ad choices. Visit megaphone.fm/adchoices

La génesis humana La evolución humana, según Darwin, no explica del todo el rápido desarrollo de nuestra especie. Los expertos investigan textos, ADN y anomalías fisiológicas para descubrir nuestros orígenes.

Could Mitochondrial Health and Cellular Aging and your unique genetic blueprint be the missing link behind your energy, inflammation, and long-term wellness?     In this fascinating episode of the Lisa Fischer Said Podcast, Lisa sits down with Dr. Sam Shay, chiropractor, genetic health expert, comedian, and creator of the NeuroSpicy comedy special. Dr. Shay explains how genetics influence everything from carb tolerance and caffeine sensitivity to exercise recovery, inflammation, methylation, and overall health outcomes.     They unpack the truth about MTHFR, why genetics are far more complex than a single gene mutation, and how personalized nutrition can outperform one-size-fits-all wellness advice. Dr. Shay also shares his personal experience with Asperger's syndrome, discusses AI's growing influence on healthcare, and explains why understanding your DNA can help you make smarter lifestyle decisions.     If you've ever wondered whether your body is wired differently than everyone else's, this episode offers practical insights into personalized health optimization.    

How much do our genes determine about our lives, and could they influence traits like risk-taking, antisocial behaviour or even violence? Ian Sample talks to Kathryn Paige Harden, a behavioural geneticist and professor of psychology at the University of Texas at Austin who studies how genetic factors shape human behaviour. In her book Original Sin she explores how nature and nurture combine to influence our likelihood of committing crimes, and asks whether the ‘cause' of our actions matters for how we think about culpability

Early signs of dementia can show up years before a diagnosis. Discover 31 scientifically proven dementia prevention strategies designed to preserve cognitive function and support long-term brain health.0:00 Introduction: What is dementia?0:42 How to not get dementia3:03 Stomach acid and dementia signs5:40 DHA to improve cognitive function7:20 Aluminum and brain function9:45 Gum health and dementia11:04 Hypoxic training for dementia prevention14:51 Keto and intermittent fasting for dementia prevention16:16 Genes and dementia

How much do our genes determine about our lives, and could they influence traits like risk-taking, antisocial behaviour or even violence? Ian Sample talks to Kathryn Paige Harden, a behavioural geneticist and professor of psychology at the University of Texas at Austin who studies how genetic factors shape human behaviour. In her book Original Sin she explores how nature and nurture combine to influence our likelihood of committing crimes, and asks whether the ‘cause' of our actions matters for how we think about culpability. Help support our independent journalism at theguardian.com/sciencepod

Genes carry the biological information to make specific living things. Evolution says that simpler living things evolved first and more complex life evolved later. This would lead us to believe that more complex living things would have developed more genes. The creation approach suggests that each creature was designed with the genetic material necessary for its survival in its intended environment. As a result, the genetic complexity of living things would be related to the way it lives, not to its place in a supposed evolutionary hierarchy.Evolutionary scientists today are puzzled with the publication of the completed genome of the common fruit fly. The fruit fly has a nervous system, complex body plan and even an immune system and is the first animal to have its genome mapped. The puzzle arises with the discovery that the fruit fly has between 13,000 and 14,000 genes. The lowly roundworm, said by evolution to be among the first land creatures, should be genetically simple, yet it has over 18,000 genes. The genetic differences between the worm and the fly speak of design. The sightless worm relies on smell to make its living, so it has about 1,000 genes involved in its olfactory system. The sighted fly relies much less on smell and has less than 100 genes for detecting scents.This simply illustrates that truly scientific findings will never contradict the Bible by supporting evolution.Psalm 119:73"Thy hands have made me and fashioned me; give me understanding, that I may learn Thy commandments."Prayer: Dear Father, help me to keep my nervous system healthy through wholesome stimulation and thoughts so that it can always be a source of my thanksgiving to You in all things. In Jesus Name. Amen.Ref: Science News, pp. 382 383, "Fly Genome Creates a Buzz." Image: APHIS-Moore Air Base, Protection and Quarantine Science and Technology Insect Management and Molecular Diagnostics Laboratory, USDAgov, PD, Wikimedia Commons. To support this ministry financially, visit: https://www.oneplace.com/donate/1232/29?v=20251111

Guest Bio: Abby Harris has a B.S. in Biological Sciences and a minor in Nutrition from Drexel University. She received additional graduate training in Nutritional Sciences from the University of Wisconsin-Madison, and has over a decade of industry and academic research experience in areas such as reproductive genetics and metabolism. Due to her passion for health and nutrition, she is currently working towards a master's in clinical nutrition. She greatly enjoys using her understanding of molecular biology, nutritional biochemistry, and research to manage report development and education at Fagron Genomics US. During her four-plus years with the company, The Personalized Weight and Nutrition Genetic Panel is one of the many projects for which she has led development.

Esta serie nos lleva al corazón de la teoría de los antiguos astronautas, revisitando los enigmas más impactantes explorados durante los últimos 15 años en la serie Alienígenas. OVNIs, dioses celestiales y secretos que podrían reescribir la historia.

A daily low dose of aspirin could significantly reduce the risk of bowel cancer in people with Lynch syndrome, an inherited condition that increases the likelihood of developing certain cancers.   In this episode, we explore the findings from the landmark CaPP3 trial, hear from a participant living with Lynch syndrome, and discuss how genomics could help shift healthcare from treatment to prevention.  Our host, Sharon Jones is joined by:  Dr Katie Snape, Principal Clinician for Population Health at Genomics England  Professor Sir John Burn, Professor of Clinical Genetics at Newcastle University  Drew Hyde, participant in the Cancer Prevention Programme (CaPP3)  Links:  Listen to: How can genomics help us understand cancer?  "I think knowing is always a good thing. And obviously, I wish I'd known earlier, and then, I could have taken more measures earlier on. So I think knowledge is definitely a good thing. And it would be great if more people could be tested or could find out if they were carriers at an early age, I think."  You can download the transcript or read it below. [00:00:00] Sharon: Welcome to Behind the Genes. In today's episode, we'll explore the research which shows how a low dose of aspirin can halve the risk of bowel cancer in people with Lynch syndrome. We'll hear about the real-life impact of living with the condition, and look at how genomics can help shape a more preventative approach to care in the future. [00:00:20] I'm Sharon Jones, and to help us unpack all of that, I'm joined by our guests, Dr. Katie Snape, principal clinician for population health at Genomics England; Sir John Burn, professor of clinical genetics at Newcastle University; and Drew Hyde, a participant in the Cancer Prevention Programme, which is also known as the CaPP3 trial. [00:00:42] So to start with the basics, Katie, can you walk us through what cancer is in simple terms? [00:00:50] Katie: Sure, Sharon. So, our body is made up of cells. Those are the building blocks that, that make us as humans and other creatures and plants. And our cells need to keep dividing throughout our lifetime as our bodies are growing and working normally. [00:01:06] And so we need to have processes in place in our body where our cells can divide, but then also stop dividing when we don't need them to carry on dividing. What happens in a cancer cell is basically that cell becomes abnormal, and it doesn't follow the normal checks and balances and rules of cell division. [00:01:23] So it starts to divide and grow uncontrollably, and it can start to invade other tissues and obviously, that can cause serious consequences. [00:01:33] Sharon: We'll hear a lot more from Dr. Katie Snape in this episode. But before we move on, I just wanted to flag that there was an episode of our Genomics 101 explainer series with Katie dedicated to helping us get to grips with how genomics can help us understand and diagnose cancer. [00:01:47] Do go and check that out. We'll put a link to that in the episode description. [00:01:54] So the World Health Organization estimates between 30 to 50% of all cancers are preventable. So, Katie, when we talk about cancer being preventable, what does that actually mean? And what's an example of cancer prevention that people might already know? [00:02:11] Katie: Yeah. So some cancers are due to chance or just mistakes happening as our cells copy. [00:02:19] Other cancers are because there has been damage to the genetic information within the cell that can be caused by certain things that can cause damage to DNA. So for example, a sort of obvious answer would be skin cancer. Skin cancers can be caused by sunlight, the, the UV light in the sun, and particularly if we burn our skin or, or get sun damage to our skin, increases the chance of us developing a skin cancer. [00:02:44] So you can think of lots of other examples such as cigarette smoking and lung cancer, and so we know that there are a number of different risk factors that increase the chance of our cells developing damage and becoming abnormal cells and growing uncontrollably. So when we talk about prevention, we might think, well, could we reduce some of those risk factors and therefore reduce the chance of those cells getting damaged and becoming cancer cells? [00:03:10] So I gave the example of skin cancer. We might put sun cream on if we're going out in the midday sun, for example. That reduces the damage of the UV light onto our skin cells. Or we might help people to go into a smoking prevention programme or, you know, other risk factors, such as we know that being very overweight can increase the chance of cancer. [00:03:31] We might help people get into more exercise regimes or improve people's diets. So those are the sorts of things that we might do sort of for environmental risk factors. But we also know, particularly in this context, that sometimes people are born, they carry genetic changes within their cells that they're born with, that are inherited, that run through families, and those can also increase the chance of some cancers developing. [00:03:56] And for those people at higher genetic risk, then we might look to other ways that we might reduce that risk. We can't change the genetic changes in their cells, but we might be able to put things in place to reduce the risk for those individuals, and that might be medication, it might be surgery, or there could be other things that we might be able to offer. [00:04:15] Sharon: Yeah, and with that in mind, is there anything more, you know, that you can share about some of those risk factors that someone is more likely to develop cancer? [00:04:25] Katie: Yeah. So actually, the, the biggest risk factor for developing cancer is age. The older we get, the more times our cells have divided, the more chance there is of a copying mistake that, that, that can cause that cell to become abnormal and start growing uncontrollably. [00:04:41] And that's why cancer becomes more common the older we get. We obviously can't change our aging process. Then, as I've said, sometimes we're born with certain specific inherited factors that increase the risk. That might be one big high-risk genetic factor, such as having a cancer gene that's important for, for that process of cell division that isn't working properly. [00:05:04] Or it could be that we have multiple lower genetic risk factors that can kind of add up together to increase the risk. And those often interplay with some of those environmental factors that we've talked about, like smoking, for example, or weight, or alcohol or other things like that. So most cancers are due to aging, and then there's a sort of interplay of genetic factors, but environmental factors as well. [00:05:30] Sharon: That's really interesting to understand. And the focus of this podcast is sort of looking at kind of Lynch syndrome and what findings have come out around aspirin and having a low dose of aspirin. So I want to kind of explore what Lynch syndrome is and, and then bring in Drew to talk about his experience of having Lynch syndrome and how he got involved in the trials themselves. [00:05:49] So from what I understand, Lynch syndrome is a genetic condition that can make some people more likely to have the chances of developing into bowel cancer. And Drew, this is your opportunity to sort of talk about what that's been like living with Lynch syndrome. And, you know, I'd like to understand more about your story and how it came about that you discovered that you had Lynch syndrome, and to share with our listeners your journey. [00:06:13] Drew: Yep. So in my case, I discovered I had the colon cancer before I discovered I was a Lynch syndrome carrier Basically, at the age of 50, I noticed some change in my health. You know, I was becoming a little bit more tired. My bowel movements had changed or whatever. So, I went to the GP and the GP basically said, "Well, you're probably too young for cancer, so let's look at other alternatives." [00:06:37] And I had blood tests and I had low iron, so I was on iron tablets for three months and whatever. Then eventually I went back and finally the GP said, "Well, let's try a colonoscopy." And the colonoscopy revealed that I did actually have colon cancer. And then very quickly I had surgery and, uh, then following that, I kind of asked the question, "Well, why me?" [00:06:59] You know, I'm only 50, 51. Yeah. You know, why me? [00:07:02] Drew: And basically, I was told, "Well, it's probably genetics." And then I was referred to, you know, St George's and Katie and I had the test and discovered that I was actually a Lynch syndrome carrier, and that's why, you know, I'd got the colon cancer at the age of 50, so. [00:07:17] Sharon: I mean, that's quite a journey. I mean, how did you feel when you're already on one pathway and then having to kind of find out more, you know, what was your experiences? What was the impact on your life? How did you, how did you feel? [00:07:27] Drew: I think I was lucky in that I had a very good surgeon. I had surgery very quickly, so that was the first hurdle. [00:07:32] Then I had to go on to chemotherapy, and the chemotherapy obviously is far worse than any surgery or anything else that comes before or after. But having got through that, then I went through the St George's onto the Lynch syndrome system. So, the most important thing then really was to basically identify what that meant for me, but also because it was an inherited characteristic, what it meant for my family. [00:07:57] One thing that was interesting, and I say, you know, the, the GP was saying, "Well, you're too young to have cancer," is that there wasn't any history of cancer in my family, you know, looking at older relatives. So, you know, to be fair to the GP, that wasn't an obvious marker. So basically, yeah, it was let's, you know, find out what it means now going forward. [00:08:21] Sharon: So, can you just take us back to when you were diagnosed with Lynch syndrome? What sort of guidance were you given at the time about managing your cancer risk? [00:08:30] Drew: Well, following the surgery, I was given various statistics which were fairly grim on what your percentage survival rate were in three years, five years, 10 years based on the surgery, whatever. [00:08:39] And that was kind of a bit harrowing. But, you know, assuming I'd get through five years, I felt it was, my chances were quite good. As for myself living with, living with Lynch syndrome, that, you know, I was aware that having had the colon cancer, I then had increased risk of other cancers. So since then, I've been on a screening programme, and I have colonoscopies or gastroscopies every year or two years. [00:09:04] So that's been very good. So, I believe now that if any other cancers were to appear, I would probably know very early on because they would be detected through a screening process before they got to a point where they would be, you know, maybe too difficult to resolve, so. So that's-- I think the screening programme, has been very, very good. [00:09:23] The main issue for me was what it meant for my family, being a genetic thing. So very quickly, my children, who were teenagers at the time, were both tested, and they went through some counselling with Katie beforehand, you know, about what it would mean for them to get a positive or negative result. [00:09:42] Unfortunately, my daughter was tested as negative, but my son was tested as positive, so he's now on the same cancer screening programme, and has colonoscopies every two years. So yeah. The mystery really, though, is where I inherited it from because my father died when I was very young. My mother was in a care home at the time, and I wanted to get her tested. [00:10:07] And at the time, her GP wouldn't test her on the basis that she was unable to give consent. But fortunately, I had power of attorney, and we could persuade him to do the test. But she tested negative. So I'm assuming I inherited it from my father's side. But most of my grandparents on that side of the family lived into their nineties without any apparent cancers. [00:10:32] So it's still a bit of a mystery how I inherited it, but what was important for me was to know which side of the family I'd inherited it from because obviously with cousins and whatever on different sides of the family, I wanted to be able to tell them what the situation was. My brother also tested negative, which was a positive. [00:10:54] So at the moment, it's just my son and I that have the defective gene. [00:10:59] Sharon: I'm sorry to hear that about your son, but does it- [00:11:01] Drew: Well, well, I mean, he, you know, he has to go through a colonoscopy every couple of years, which, you know, obviously is not a pleasant experience. But at least he knows that, you know, the first sign of any problem, the medics will be aware of it, and he'll be able to react. [00:11:16] Sharon: Has it changed your outlook on life, having this window in possibly knowing stuff or not knowing stuff? How has that affected you and, and your son as well? [00:11:25] Drew: I think knowing is always a good thing. And obviously, I wish I'd known earlier, and then, I could have taken more measures earlier on. So, I think knowledge is definitely a good thing. And it would be great if more people could be tested or could find out if they were carriers at an early age, I think. [00:11:42] Sharon: Yeah. That is really important. And moving into about the trial more broadly, scientists have known that there's been a link between cancer and aspirin for some time, with fewer cancers observed in people who take aspirin. So coming to you, John, could you share a bit more about the history of inherited cancer research and how the focus of Lynch Syndrome came about? [00:12:02] Because this isn't new, is it? [00:12:06] John: No, absolutely, Sharon. And in fact, this story, my story in this space begins 40 years ago when I was one of the geneticists who set out to try and find the genes that we've just been talking about. At that time, the group of patients who were the most obvious to begin with were young people with a condition called familial adenomatous polyposis, or FAP for short. [00:12:26] And they'd get thousands of polyps in their bowel, and the only way to treat that was to actually remove the whole bowel when they reached adulthood, which is a fairly extreme intervention. And I was running, I was setting up a registry. We were trying to find the gene at that time, and we'd just found it, in fact, but we also were trying to find all the families. [00:12:44] And I'd taken over responsibility for all the genetic services in the north of England, in the North East and Cumbria. And we'd, I'd started identifying families with FAP, and we went to visit one of those families, and this was the kind of light bulb moment for me because I walked into the room and mum had had her colon removed, and her son, Jonathan, had just had his first colonoscopy at the age of 12, and it was clear. [00:13:07] And I was about to give them the good news, but as I walked in, I noticed that he had little bumps on his forehead called osteomas, little bony bumps. His mother had them just the same, and it was one of the features of this condition. So I knew he had the gene even though he hadn't yet got the polyps. [00:13:21] Sharon: Wow. [00:13:22] John: And it made me think, wouldn't it be nice if we could do something to prevent these things happening rather than just waiting for an operation? And as it happened at the time, I was leading the English end of a big study, which you'll probably be aware of, which we're, we're, we were doing the vitamin study on women with spina bifida babies, and we were just about to identify folic acid as a way of preventing spina bifida in pregnant women. [00:13:45] So I had these two thoughts in my head. Maybe we could set up a trial like this folic acid trial, and then one of my friends in Edinburgh said, 'Have you seen this paper from Melbourne?' Gabriel Kuhn had just done a big study looking at people with colon cancer. It seemed that people who took a lot of aspirin didn't seem to get as much bowel cancer in Melbourne as those who didn't. So that was the design set up. [00:14:08] We were applying to Europe for a concerted action, so we had to think of an acronym that began with CA. So I, I came up with Concerted Action Polyp Prevention. But then in 1993, just as we started that trial, we were involved in finding the first of the genes for Lynch syndrome. We had a big family in Northumberland where there were lots of people like Drew's family, and there were three generations of cancer in the family. [00:14:31] So CaPP2 was immediately born in my head. In 1999, we had our first recruit, and we recruited until 2005. We found, in total, 1,000 people in 16 countries to join in, and we gave them two aspirins a day or two dummy tablets. Two aspirins is quite a big dose, but back in my day when I was a junior doctor, we used to give many more tablets of aspirin to people with arthritis. [00:14:57] So two tablets wasn't such a big deal. Nowadays, it's seen as a very high dose. And it worked. Basically, to cut to the chase, when we looked in 2010, the people who were getting the aspirin were getting less bowel cancers. In fact, it was a 50% reduction. So the people who took two aspirins had half as many bowel cancers and fewer cancers of other types as well. [00:15:19] We realised, although, at this point, immediately we saw that it was working, we knew we'd need to do another trial to see whether a smaller dose of aspirin would be just as effective. So CaPP3 began, and the great news is that what we'll be reporting in the journals in the next few days when it gets published, is that the people who were taking  CaPP3 aspirin in any dose were tracking exactly the same as the 600-milligram group in CaPP2. [00:15:46] So we're pretty sure that it works. We're pretty sure that the small dose is just as good. And the great news was that we had fewer side effects in that group. And so in fact, no one had to go to hospital for a transfusion or anything, you know, like that. Whereas in the 600-milligram group, we had a few people who needed treatment because, as you know, and everyone knows, if you take aspirin, there's a higher chance of having an ulcer that causes a bleed. [00:16:10] And that was always the anxiety. But people like Drew were courageous enough to take the chance because they knew we needed to know the answer to this. And of course, when you compare it to the risk of getting cancer, taking an aspirin is a relatively small risk. [00:16:26] Sharon: So, what were your kind of considerations when you were designing the trial, having that knowledge? [00:16:32] John: Well, the first thing is it has to be fully informed consent, which means that you have to explain to people what that risk is. The important thing about aspirin is that doctors have a much worse opinion of it than it deserves because if you work in a hospital, you'll often see people coming in who've had a bleed. [00:16:48] It's not always caused by the aspirin. The thing is, if you're coming with a bleed and you're on aspirin, everyone blames the aspirin. Right. About half of them would've happened anyway. In fact, the, the irritation of the stomach is much more of a problem in older people So in fact, the average age of the people in CaPP2 and CaPP3 was about 45, 46 when they started. [00:17:08] Drew was a little bit older, but, but people in that sort of middle age group are much, much less likely to get into trouble than people in their 70s and 80s. And it's people also who've had a history of ulcers that have a bigger problem. We also knew that if you had a stomach infection called H. Pylori, which is itself a risk factor for cancer, and about one in six people carry that bug, and we knew that if we fixed that with antibiotics, that would significantly reduce the risk of bleeding as well. [00:17:37] So it was a manageable risk. It was something we could share with people. They knew they were taking a bit of a chance. But actually a good way of putting it in terms of the risk, for people in middle age, the risk of a low dose of aspirin is about the same as the risk of having a colonoscopy, which is very small, but it isn't completely without risk. [00:17:56] Sharon: Yeah, and Drew, kind of like hearing this sort of incredible, like, backstory about how we've got to these trials and where we are today What was your experience like as a kind of participant of this trial? [00:18:08] Drew: I understood I was going to be on 100, 300, or 600, but wouldn't know for at least three years, or was it five years? I can't remember. [00:18:15] And then sometime later in the post we got these packs, and it was ... I remember at the time thinking it was like a rather dull advent calendar - ... in that you'd have the days of the week- ... with the little, with the little windows, and you'd, you'd pop the tablets out three times a day and take them. [00:18:31] So I did that. I think, you know, I, I don't think I ever missed a day or whatever. Initially, I thought I must be on a really low dose, because I didn't actually notice any side effects. You know, I remember saying to my wife, I said, "Oh, I think I must be on the lowest dose, because I don't see any side effects." [00:18:46] It was a surprise years later when I was told actually I'd been taking 600, so. [00:18:51] Sharon: Wow. [00:18:52] Drew: It was quite an easy experience really. [00:18:54] John: We had a lot of problems. We had to pack the aspirin in six-month packs, because it was very expensive to pack this stuff up. It cost... We got the aspirin free from the Bayer company, but it cost us more than a million pounds to actually put it in, in the packs to satisfy the regulations. [00:19:10] Uh, and a lot of people complained that the packs were a bit big and awkward, but that was just, you know, a constraint. But it was not that big a deal once people got into it. But we did get a lot of complaints about the size of the packets, which we couldn't do anything about that. [00:19:24] Drew: They came regularly through the post, and, you know, so every three months or whatever I got another supply, and I just carried on taking them. [00:19:30] Yeah, so. [00:19:31] Sharon: What was going through your mind when you were kind of waiting for this potential outcome, Drew? Because you, like you say, it was, you know, it was a long time taking part. What was... Especially as you were opening your, you know, your package a day, knowing exactly what you were going to get. [00:19:44] Drew: Well, I, I kind of knew it would be a long-term thing. [00:19:47] I think I was committed for five years initially. But I carried on taking the aspirin for another probably five years after that. So yeah, I was just sort of happy to take the aspirin and then sort of wait to see what the results would be. As I say, that I didn't really notice any side effects, so I wasn't really worried that it was having any detrimental effect on me. [00:20:09] So I was curious to see what the, what the results would be. [00:20:12] Sharon: Yeah. John, the trial has provided like the evidence that, you know, low-dose aspirin can prevent bowel cancer. But are there any challenges that still exist with translating this research into clinic and ultimately patient care? [00:20:26] John: Well, yes, and I'm going to hand back to Katie, who's actually leading the charge on, on getting it into practice as well. [00:20:32] But just to say that I, I'm actually now literally on my other computer finalising my bid to go back to Cancer Research UK because we want to go for three more years. Wow. We said that we would follow people for 10 years after they'd finished their ... or after they'd started, so, you know, for at least 10 years. [00:20:50] So the last person to join didn't finish until 2024, so we won't get to that person. It's Robin and one of my patients. We won't get to Robin's 10-year anniversary until 2029. Oh, yeah. By which time, obviously, Drew will be even further on. But that will give us at least 10 years of follow-up because we know that there is this delayed effect, and that was seen right back at the beginning when people looked, for example, the nurses study in America, where they followed 86,000 nurses and just asked them if they took aspirin. [00:21:18] And nothing happened for 10 years, but those who were taking aspirin for more than 10 years saw a benefit. So in the general population, it probably takes that long to kick in. And so we need to keep going for just a while longer. It's not as expensive now because we're not giving people aspirin anymore. [00:21:33] Sharon: Yeah. [00:21:34] John: But one of the reasons we g- we made Drew's dose blind was because we wanted to know what the side effects would be when you didn't know how much you were getting There's a danger if you're getting a higher dose, you're more likely to complain. And actually, it did work out that the people on the lowest dose had the fewest side effects, even slight side effects. [00:21:51] The only thing we can't escape from is if you're taking aspirin, you get bruising more easily because it blocks the platelets, which are the little tiny blood cells which plug up little holes in your blood vessels when they leak. The good news is we now know that platelets turn out to be right, a major factor in triggering cancer. [00:22:09] And so the aspirin, by blocking the platelets, is actually reducing the risk of cancer, but also reducing the risk of cancer spreading in the body. So this is new research, and we've got another big research project in collaboration with a team in Cambridge who are, uh, pursuing this. Also, the other exciting news is that my other partner, Ruth Langley, is running a big trial of people with cancer, and those who are given aspirin as part of their treatment have less likelihood of getting spreading cancer later on. [00:22:39] So the aspirin is clearly doing something good at many levels in the system. Surprisingly, and we think it might be partly, partly because we used to have a lot of salicylate in our diet, which is what aspirin's made from. And we think that maybe we're putting back something that the body actually was used to having. [00:22:57] Yeah. But modern diets don't contain any, any salicylate because of the way we prepare our food. So it may well be that a little bit of aspirin's a good thing for everybody, but obviously, that's a choice that each person will have to make. [00:23:09] Sharon: Yeah. I mean, it's a real powerhouse of a, of a drug essentially, which you're finding out more about its benefits as, uh, as research goes on. [00:23:18] So Katie, can you just give us a bit of a broad overview of Genomics England's new adults program, which is kind of looking at this sort of area of work and, and what, how can it benefit people? [00:23:29] Katie: Yeah. Thank you, Sharon. So, the adults programme at Genomics England is being funded by government, and the government wrote about it in the 10-year NHS Health Plan, the Life Science Sector Plan to run a large-scale genomics population study. [00:23:44] So looking at how we can obtain genetic information from people in the population and look at more proactive and preventative healthcare, and can we generate evidence on where, how, and why the NHS should start applying genomics into kind of more population health measures. So, there's sort of two sides to this. [00:24:05] So the first is thinking about pharmacogenomics, which is basically about how genetic factors influence how we respond to drugs. So lots of people have had experiences of having side effects from drugs, we've just been talking about that with aspirin, or for drugs not working so well for them. And we know that there are certain drugs that genetic factors can influence whether you should take the drug at all, or if you do, what dose you should take, whether it's going to work for you or not, whether you might be more likely to get side effects or adverse reactions. [00:24:34] So part of the programme's looking at that. And then the other half of the programme will be looking at sort of is, are the genetic factors relevant for sort of serious and high-risk conditions in the adult population? So we could take bowel cancer as an example of that, a common condition, breast cancer, you know, common cancers or cardiovascular disease. [00:24:58] We know there are certain genetic factors for some people that have significantly increased their chance of developing those serious adult onset conditions. Can we find those people in the population and then put measures in place to prevent that? So, you know, even just thinking about Drew's story, he didn't have a family history of cancer. [00:25:16] The first time that he knew he had Lynch syndrome, he'd already developed bowel cancer. And we know that many people that have Lynch syndrome or other high-risk cancer genes are unaware of their status in the population, and so, um, the idea of this program is to really look at, well, if we were to, to look for some of these very high-risk genes in the general population, could we then put measures in place to reduce the chance of them developing the serious condition as a consequence? [00:25:44] So instead of Drew presenting with his bowel cancer, we'd actually already picked it up, despite the fact he doesn't have a family history, and we'd offered him, let's say, aspirin if we'd known the information at the time, and we could maybe have prevented him from developing bowel cancer. [00:25:58] So it's really exploring looking at that a little bit more. [00:26:02] Where can we get genetic information in the population? Where might there be a really well-evidenced, like all the work John's done over 40 years, is really well-evidenced now. Yeah. Yeah. Where are there these opportunities for us to turn the dial on some of these common adult onset conditions? [00:26:20] Sharon: What other challenges do you think with getting this out there do you see? [00:26:25] Katie: Uh, I think there's, there's lots of challenges. I think it's a really com- ... complex programme of work. The first thing is that the risks might be different for people in a population than have a family history. So where I've worked for, for years, and John as well in, in clinical genetics, we've seen the highest risk people, the people with lots and lots of cancer in their family because they're the people that are presented to healthcare services. So we've worked out the risks based on that population. It will be really different when we move to the population setting. We'll find fewer people, and the risks might be lower because there might be other factors that are giving them a lower risk. But that's not to say the risk is zero. [00:27:05] It's probably still raised. So then what we need to do is we need to consider, okay, well, what can we do to intervene, taking into account this change of context from people that we found through clinical services to people that we see in the population. And aspirin is a great example of this. [00:27:22] So, you know, if we find that someone has a Lynch syndrome gene, then taking aspirin, unless there's a really good reason for them not to take aspirin, is almost certainly going to be low cost to the NHS and really significantly reduce the chance of them developing bowel cancer with a low risk profile. So where are those opportunities? [00:27:41] And that isn't clear cut, and that's why we need a large scale research programme that can try to help the NHS answer some of those questions, so it can decide how best to spend its money in, in the people that are most likely to benefit from it with the least amount of risk or harm to them. [00:27:58] Sharon: That makes sense. And, and so, you know, going to you, Drew, what are your kind of thoughts on some of the challenges that Katie's highlighted? And is there anything else that you think needs to be improved in better supporting people living with inherited risk of cancer in the future? [00:28:14] Drew: In the brief sort of 10, 15 years or whatever since I've been s- suffering, awareness has increased greatly. [00:28:21] I mean, for example, my GP now knows about Lynch syndrome, whereas I don't think she did when I was first diagnosed, and I think there is a little bit more awareness out there, but I still think it's a lot less than there would be for, say, for breast cancer. So for example, when a high-profile personality reveals they've got breast cancer, you often get information about inherited risks. [00:28:44] You don't seem to get that with colon cancer. You know, when it's announced that so-and-so has died or is whatever, you don't get that same, you know, it, it might be a genetic thing. I mean, when I was first told people that I had bowel cancer, the response I got usually was, "Oh, poor diet, was it?" [00:29:04] And I always felt a bit upset, that, you know, actually my diet was fairly healthy. And that was the assumption that people had. So I think anything that gets the message out there that there is a risk, an inherited risk, I'm not sure what the statistics are now, Katie, is it one in 400 people might be a Lynch syndrome carrier or something like that? [00:29:24] You know, it's relatively high for something that is, if you know in advance you're at risk, you can do something about it. But like me, you know, I waited until it was too late, because I didn't know, and then had to have the surgery, so anything that promotes the message that there is a risk. I know some people don't want to know about their genetic makeup. Obviously, that's a choice. But I think to give people, as many people as possible, the choice must be a good thing. [00:29:54] Sharon: Yeah, absolutely. And I think one thing I've noticed through this thread is the sort of theme of funding and what gets funding and the amount of time it takes to, to kind of get that funding. [00:30:05] Is there anything you wanted to add around the kind of funding model, around why some things get funded, you know, uh, more prominent, like Drew's point, obviously, talks about if someone high profile kind of comes forward and says XYZ, that gets the spotlight shone on it, and there might be research going that direction compared to s- to, to other cancers. [00:30:23] John: So maybe I could speak at that. So partly because of my experience, I've now been made chairman of the grant committee at Cancer Research UK for prevention and population research. And there is a real drive to push more resource into prevention for the obvious reasons. [00:30:39] Katie: Yeah. [00:30:39] John: And also, it's got to be remembered, it's very difficult for the drug companies to fund this because it takes such a long time that the drug's- Mm [00:30:46] out of its patent before they actually get to use it. So, it's very difficult from a business point of view to fund research into prevention. But they are keen to help us, uh, but we really need sort of central government and the charities to focus on prevention if it's going to make a difference. [00:31:02] And just on Drew's point on diet, I mean, diet is still important even if you have Lynch syndrome. In our CaPP2 trial, the people who were overweight were more than double the risk of cancer. So it's not like an either/or. If you've got a higher genetic risk and you have a bad diet, then that's, you know, is going to contribute. [00:31:21] But the other exciting thing is, of course, we now have medical ways of treating obesity in, in people. So, one of the interesting areas is whether we should be, in the same way as we are for other high-risk populations with overweight, we should be giving overweight people with Lynch syndrome, help to lose weight because that will also reduce their risk. [00:31:41] It's also worth just dropping in at the last moment here is that this is also a good news story in terms of treatment and further prevention. We now have a new class of drugs called immune checkpoint inhibitors, which specifically target the types of cancer that Drew had and are much more effective in curing them And also, we've just been given funding to do a project called LynchVax, which I'll be helping with, but it's led by David Church in Oxford. [00:32:05] And this is developing a vaccine against cancers in people with Lynch syndrome. The great news is it'll probably work alongside aspirin because we know the aspirin is enhancing the immune response. So the two together may make this a curable condition. [00:32:18] Sharon: That's actually incredible. I mean, that, it gives so much hope for people. [00:32:23] And I just wanted to find out if you had any more kind of reflections as we close, because we're going to come to the end of our podcast today. If there's anything more that you wanted to share, anything that has been missed, or anything that you want our listeners to know, and I think I'm gonna come to you, Drew, first, because you're the person who's had to sort of live through this and, and go through this journey along the way. [00:32:41] Drew: I think just basically, if you're not sure, get tested. Obviously, there are financial constraints. I'm sure that running a DNA test is quite an expensive business. But I think if you've got any history of bowel cancer in the family, you've got any concerns about your health, speak to a GP and see if you can get tested as quickly as possible. [00:33:00] And then, to get a better message out there that there are risks of inherited colon and other similar cancers, so. [00:33:11] Sharon: Yeah, so it's getting that, messaging out, um, for people to understand more and make those informed choices. And Katie? [00:33:18] Katie: I mean, I would say that the power of, of our, you know, NHS and our academia and, and our healthcare system has been collaboration. [00:33:26] Sharon: Yeah. [00:33:27] Katie: There's so many moving parts. There's commissioners, there's funding, there's the evidence, there's research, there's healthcare implementation. The UK's a really amazing place to work in genomic medicine, and I think that's partly because of the amazing collaborations that we have, and the way that we can translate research into healthcare as John's team have done with this amazing study. [00:33:48] So let's all keep working together, please. [00:33:52] Sharon: Absolutely. And John, it feels like this is your lifetime's work. [00:33:58] John: Well, I've become aspirin man, it wasn't intended. But Katie's done fantastic work in her role as chair of the Cancer Genetics Group in the UK, so we've now implemented a, [00:34:06] we're the first in the world to really make this an absolute directive to the GPs and all, to all doctors to say, "People with Lynch syndrome need to be offered aspirin." And so that's a great step forward. But we also need to get it into the British National Formulary, and I'm working with their team so that the GPs are empowered to do this. [00:34:24] It's actually part of their care package. But I would just say we've still got a long way to go. We've now got a national list of all the people with Lynch syndrome, like Drew, to make sure we offer them all a colonoscopy, but there are only 14,000 people after several years of really pushing. [00:34:40] Sharon: Right. [00:34:40] John: We think in the national population in all ages, it's about 1 in 300. That's a lot of people. That means there's about 150,000 people like Drew in the country, and we've only found 10% of them. So we can't just rely on family history for all the reasons Drew explained. You know, I mean, Drew's dad probably died of Lynch syndrome, but we don't know because we've lost that record. [00:35:02] So now we're checking every bowel cancer to see if it might be caused by Lynch, and that programme is now kicking in, and we're picking up a lot more gene carriers as a result of that. But there's still a long way to go to get co- get people aware of Lynch syndrome, to think of it when someone presents with a cancer, not just of the bowel, but in the womb, in the kidney, in other parts of the body. [00:35:23] It's not just the bowel, but that's the most important group. [00:35:26] Sharon: Yeah. [00:35:26] John: So there's still a long way to go. [00:35:28] Sharon: Where you've come to now is still an incredible achievement, even though we've still got a long way to go, and I don't think we should ever lose sight of that. So we're going to wrap it up there. Thank you to our guests, Katie Snape, Professor Sir John Burn, and Drew Hyde, for joining me today as we discuss cancer prevention. [00:35:48] If you'd like to hear more like this, please subscribe to Behind the Genes on your favourite podcast app, and thank you for listening. I've been your host, Sharon Jones, and Behind the Genes is produced by Deanna Barac, Florence Cornish, Sophie McLachlan, and Dave Howard at Bespoken Media.  

Hosts: Ed Jones (Owner – Nutrition World) & Clint Powell A variety of topics all related to living a healthy life Presented by: Nutrition World www.nutritionw.com Broadcasting from the Nooga Dentistry Studio www.noogadentistry.com Production of: Whitfield Media Group www.vitalhealthradio.com Title: Peptides, AMPK, and Other Supplements for Weight Loss.  [0:00:00] Headlines, Glucosamine & Alzheimer's, and Study Skepticism Ed recaps last week's episode about truly high-quality eggs and how to tell if eggs are nutritious Mentions Kristy (“chicken whisperer”) and that her eggs are sold at Nutrition World. Ed addresses a national headline claiming glucosamine may accelerate Alzheimer's. Explains it was an observational study based on medical records, not a controlled trial. People who start glucosamine often already have joint pain, inflammation, or cognitive decline. This creates confounding factors (correlation ≠ causation). Even broad AI-style review of research finds little credibility for the idea that glucosamine worsens Alzheimer's and notes that some data suggest potential benefit. Clint and Ed discuss: How people often change multiple habits at once when they get sick (diet, supplements, etc.). The importance of baseline data (bloodwork, journaling) before judging if changes work [0:13:29] Guest Elisha: What Peptides Are & How They Can Assist Weight Loss Elisha from Nutrition World is introduced. Ed recounts his history with weight-loss supplements: Heavy use of ephedra in the '80s and '90s: effective but with side effects (nervousness, blood pressure, insomnia). Ephedra was eventually banned; Ed largely stopped promoting weight-loss pills, focusing instead on lifestyle, macros, and exercise. Ed admits he dismissed Ancient Nutrition's new Active Peptides at first, assuming it was a label trend riding on the buzzword “peptides.” Reports strong positive feedback from real customers, including many who are not heavy supplement users but want help with appetite and weight. Elisha  explains peptides with a “pearl necklace” analogy: A full necklace = protein. Individual pearls = amino acids. Small segments of the chain = peptides, which act like signals or “text messages” in the body. Distinguishes nutritional peptides (like in this product) from therapeutic/medical peptides (e.g., GLP‑1 drugs). Describes DNF‑10, the peptide in Active Peptides: A three‑amino‑acid chain isolated from baker's yeast (Saccharomyces cerevisiae). Modulates appetite‑related hormones: Ghrelin (“hunger hormone”) – DNF‑10 helps reduce ghrelin signaling so you feel less hungry. CCK (cholecystokinin) (“fullness hormone”) – DNF‑10 helps increase CCK, making you feel full/satisfied sooner. Elisha's personal experience: Used it to help lose a few pounds before her wedding and to control cravings after a carb‑heavy honeymoon in Italy. Reports feeling less snacky in the afternoons despite the tempting snacks at Nutrition World. Notes customers are consistently “wowed” by the effect on appetite Product forms and dosing: Powder in flavors like guava grapefruit and chocolate (which she says tastes like brownie). Capsules: typically 2 per day. Can be mixed with: Ancient Nutrition's A2 protein powder after lunch. Or simply with water. [0:24:35]  AMPK, Berberine & Metabolism Support Products Alicia introduces Life Extension AMPK Metabolic Activator: AMPK is described as a master cellular switch in every cell — like the light switch in your house showing you what needs cleaning. Supports cellular cleanup and improves handling of belly/visceral fat, the dangerous fat around organs. Typical study protocol: 12–16 weeks (3–4 months) for notable changes. Usually 1 capsule per day. Ed references Dr. David Sinclair and the role of AMPK (and NMN) in longevity, noting strong safety when aiming to restore normal function, not push extremes. Berberine: Also activates AMPK. Mimics some effects of metformin: supports blood sugar balance and metabolic health. Very safe overall, though some experience GI upset; Ed notes finding a brand that minimized stomach issues. Nutrition World pharmacist Dr. Curt Dearing frequently recommends it. Life Seasons Metabolism Formula: Designed to boost resting metabolic rate rather than affect satiety. Key ingredients mentioned: Green tea (thermogenesis) Cayenne pepper (metabolic “furnace”) Theobromine (mild stimulant for energy without jitters) Theanine (calming) Cacao (hormonal and metabolic support) Green coffee bean (via chlorogenic acid; supports liver and moderates sugar release, especially in fasting). Ed recalls the Dr. Oz–era fad around green coffee bean and notes that while it was overhyped, it does have real, modest benefits when used correctly and not as a “magic pill.” Ed describes his own experience: Training for the Chattanooga Fitness bodybuilding event. Cut calories by ~40% for the first time at age almost 69, but only lost about 7 pounds, illustrating slower metabolism with age. Elisha emphasizes: These products are tools, not replacements for macros, exercise, and lifestyle. Goal is to raise resting metabolic rate and support what diet and training are already doing. Elisha notes peptides are fine in the evening (non‑stimulating) but the Metabolism formula should be used earlier in the day due to its stimulating ingredients. [0:37:39] Aging, Eye Strain Ed reframes healthy aging: Less about reaching extreme ages (e.g., 120+) and more about strength, clarity, mobility, and energy in the years you do have. Notes concepts like a “heartbeat quota”—a rough idea that we have a finite number of heartbeats. Discusses modern eye strain from constant near‑focus screens: Historically, humans mostly focused on distant objects. Screen use reduces blinking from about 15 times/min to 5–7 times/min, leading to dry, strained eyes. Recommends the 20‑20‑20 rule: every 20 minutes, look 20 feet away for 20 seconds. Mentions lutein and zeaxanthin from green vegetables as supportive eye nutrients. [0:40:51] Teflon, & philosophy on chemicals Ed shares a household tip: He uses green, non‑toxic stainless steel cookware (360 Cookware) but scrambled eggs stick badly. His sister suggested Dawn Powerwash, which worked exceptionally well on the pan. Clint notes he uses non‑stick pans where food slides right out. Ed warns: Many non‑stick pans (e.g., classic Teflon) can contain “forever chemicals”, potentially harming hormones and long‑term health. Philosophical tension: Show is generally pro‑“green pharmacy” and low‑chemical living, but Ed acknowledges sometimes selective use of effective products (like Dawn Powerwash) can be very helpful if used sparingly and thoughtfully. [0:42:15]  Intermittent fasting & hair loss Ed shares findings from a new research study linking intermittent fasting with increased hair loss: During fasting, the body shifts from glucose to fat as fuel. Hair follicle stem cells strongly prefer glucose; forcing them to rely on fat can stress or damage them. Fasting may flood follicles with toxic fatty acids, especially in the presence of widespread seed‑oil consumption (canola, generic “vegetable oils,” etc.). Reinforces Ed's long‑standing reservations about intermittent fasting: Risk of insufficient protein, leading to muscle loss and higher mortality. Harder to build muscle within a restricted eating window. Adds this hair loss risk as another factor against aggressive fasting for many people. [0:44:59] Tinnitus & diet Study highlights dietary links for tinnitus (ringing in the ears): Higher fruit consumption correlates with lower odds of developing tinnitus. Butter and legumes appeared to calm tinnitus symptoms. MSG and aspartame/Nutrasweet can worsen tinnitus by overstimulating nerves. [0:46:00] Safer bug repellents Ed discusses concerns with DEET: Effective but not ideal for frequent or heavy use, especially on children and over large skin areas. Introduces picaridin (he pronounces it like “Picardian”): 20% picaridin spray is comparable to DEET for repelling mosquitoes and ticks. Has a better safety profile, less damaging to fabrics, and is Ed's top chemical alternative to DEET. Natural/green options: Lemon eucalyptus oil and similar formulas can repel mosquitoes for up to 6 hours. Nutrition World carries options like Trek and “Extra Strength Tick Repellent,” which Ed's family uses directly on skin, especially for his grandkids. [0:54:08] Resistance Training, Longevity, Mindset on Medicine vs. Nature Ed cites a study from the British Journal of Sports Medicine: 90–119 minutes per week of resistance training associated with: 13% lower all‑cause mortality. 19% lower cardiovascular mortality. 27% lower mortality from neurological diseases, particularly dementia‑related. Reiterates: Exercise is the most reliable “elixir” of longevity. Emphasizes that quality of life and cognitive health are at least as important as adding years. Ed quotes Andrew Kaufman, MD, who advocates: Strong belief in natural healing and the body's innate ability to self‑regulate. Skepticism toward new pharmaceuticals and product trends. “Your body is always working in service to your healing.” Ed adds his own nuance: There is an important role for short‑term pharmaceuticals, surgeries, and acute interventions when life‑saving. But defaulting to nature and lifestyle first, with drugs as Plan B, is his guiding model. Clint points out that practitioners who have worked both in conventional and integrative spaces can often offer the best balanced guidance, understanding both toolkits without being dogmatic. [0:56:15]  Final reflections & closing Ed summarizes: The world can be divided into “learners and non‑learners,” and listeners of the show are very much in the “learner” camp. The show's mission is to give practical, immediately usable health strategies that often aren't emphasized in conventional appointments. Clint highlights: We can't control everything (genetics, some disease), but having things we can control (diet, movement, sleep, supplements, environment) gives confidence and calm. Ed emphasizes the phrase: “Genes load the gun; lifestyle pulls the trigger.” Good habits can keep risky genes silent much longer The post Radio Show / Podcast – June 21, 2026 first appeared on Vital Health Radio.

Genes_Friend_Carol_Is_Kidnapped

Doctor Asa is America's Health Coach and Trusted Voice on Longevity and Human Potential.   Get Your FREE Dr. Asa Best-Selling Book at: https://www.MyFreeHealthBook.com   Join Our VIP Health Community https://www.drasa.com/vip   Visit Us At Our VIP Health Retreats https://www.drasa.com/retreats/   Visit Our Local Providers https://www.drasa.com/find-a-provider/   Become motivated and reach the best version of you by listening to The Dr. Asa Show created by Dr. Asa Andrew, MD, DC, ND, is one of the worlds only 3-doctorate physicians yielding a unique perspective between traditional medical and natural-based health information is board-certified in clinical nutrition.   Doctor Asa, or Dr. Asa, a fitness enthusiast who hasn't missed a day of exercise since he started at age 17, teaches on performance and longevity, founder of the largest health-focused television, radio, and digital network, #1 sought after speaker, best-selling author, Reality TV producer, CEO, entrepreneur, and creator of the largest multi-platform health media company with a 35+ million potential reach, which hosts the #1 Ranked 3-hour syndicated daily health talk show. On his daily radio and television programs, The Dr. Asa Show, Dr. Asa Andrew answers questions on subjects like longevity, human potential, health, personalized nutrition, fitness, medicine, lifestyle, psychology, and you will find a blend of the radio show, special celebrity interviews, #AskDrAsa, Q&A, keynote speeches, Reality TV, and the overall journey.   Oh and Doctor Asa is also The Ringside Physician and Top Heal of Professional Wrestling with TNA Wrestling and partnership with WWE and still competes in the ring.   Have a Question? Call Me 1-888-283-7272 Text Me 1-407-255-7076 DM Me  @DrAsa Email Me  Ask@DrAsa.com

Genetic testing opens the door to truly understanding who we are in ways we never imagined. In this episode of Live Foreverish, Dr. Mike and Dr. Crystal sit down with Abby Harris, the Science Product Manager at Forgan Genomics US, to discuss a personalized weight and nutrition genetics test. She shares how this test fills in gaps and how it allows an individualized approach to managing health beyond family history to help individuals and clinicians prioritize effective interventions and improve adherence to health goals. #LELEARN #EDULFsocial Guest Bio: Abby Harris has a B.S. in Biological Sciences and a minor in Nutrition from Drexel University. She received additional graduate training in Nutritional Sciences from the University of Wisconsin-Madison, and has over a decade of industry and academic research experience in areas such as reproductive genetics and metabolism. Due to her passion for health and nutrition, she is currently working towards a master's in clinical nutrition. She greatly enjoys using her understanding of molecular biology, nutritional biochemistry, and research to manage report development and education at Fagron Genomics US. During her four-plus years with the company, The Personalized Weight and Nutrition Genetic Panel is one of the many projects for which she has led development.

Habemus Papam.Una historia de poder: 1- Los orígenes

El registrador Hernán Penagos habló en 6AM W sobre la jornada de segunda vuelta presidencial en Colombia que se lleva a cabo este 21 de junio.

What if 90–95% of cancers weren't written in your genes—but in your environment, lifestyle, and daily choices? My guest today Dr B challenges some of the biggest assumptions in modern medicine, drawing on decades of experience examining cancer cells under the microscope. From the hidden drivers of chronic disease to the controversial role of hormone replacement therapy and the critical importance of gut health, this episode explores what happens when we stop asking what disease a person has and start asking why they developed it in the first place.With an unprecedented five board certifications, Dr. Monisha Bhanote brings a comprehensive, systems-based approach to health that few practitioners can match.As the founder of WELLKULÅ and CEO of Travela Wellness, Dr. Bhanote has created comprehensive platforms that make transformative health accessible to individuals and organizations worldwide. Dr B's work bridges the gap between ancient wisdom traditions and modern molecular science, creating personalized, actionable protocols that deliver measurable results.Her clinical and research focus centers on the microbiome-brain-longevity axis—investigating how gut health, inflammation management, and cellular optimization.Contact:Website - https://www.drbhanote.comJoin us as we explore:Breaking genetic dogma once and for all around disease pathology - from cancer to diabetes. Balancing the pros and cons of any approach whether conventional, Pharma or Ayurvedic.A long ranging conversation on hormonal replacement therapy. Tumor vs healthy cell biology.The crisis of gut health, the gut “clock” you didn't know you had and why many answers lie with the millennia old wisdom of Ayurvedic and Chinese medicine.The stress travel puts on your microbiome due to stress, dehydration, hypoxia, humidity, radiation and poor food choices.MentionsStudy - The Negative Influence of Air Travel on Health and Performance in the National Basketball Association: A Narrative Review, https://pmc.ncbi.nlm.nih.gov/articles/PMC6162549/Support the showFollow Steve's socials: Instagram | LinkedIn | YouTube | Facebook | Twitter | TikTokSupport the show on Patreon:As much as we love doing it, there are costs involved and any contribution will allow us to keep going and keep finding the best guests in the world to share their health expertise with you. I'd be grateful and feel so blessed by your support: https://www.patreon.com/MadeToThriveShowSend me a WhatsApp to +27 64 871 0308. Disclaimer: Please see the link for our disclaimer policy for all of our content: https://madetothrive.co.za/terms-and-conditions-and-privacy-policy/

Many disease‑causing genes are too large to be packaged into standard AAV gene therapy vectors, leaving a long list of otherwise gene-therapy-ready conditions without viable treatments. SpliceBio is leveraging a protein splicing platform based on engineered split inteins to overcome the cargo limitations of AAV gene therapy vectors, enabling delivery of large genes to potentially treat a broad range of monogenic conditions. The company's lead program is a dual AAV gene replacement therapy to treat Stargardt disease, a rare inherited condition that causes progressive vision loss. Miquel Vila-Perello, CEO of SpliceBio, discusses the company's platform technology that enable to the delivery of large genes in AAV vectors, its work to date in Stargardt disease, and preclinical data across more than 20 large-gene targets supporting its platforms use in ophthalmology and CNS indications.

Send us Fan MailToday on Move Daily Talks, I'm joined by Natalie Samson, an integrative board-certified genetic counselor and founder of Golden Genetics.Natalie helps people use genetic information to make more personalized decisions about their health, nutrition, prevention, and longevity. But how much can our genes really tell us? And is genetic testing worth the investment?In this conversation, we're exploring the science behind genetic testing, who may benefit from it, what it can and can't tell us, and how genetics fits into the bigger picture of healthy aging.Let's dive in.Follow Natalie hereGolden Genetics InstagramWebsite4 P Framework QuizJoin Move Daily MembershipFOLLOW ALONG with Move Daily Fitness!Follow on InstagramFollow on FacebookIndemnity** All information provided by Move Daily Fitness and Tracy Steen is of a general nature and is furnished for educational/entertainment purposes only. No information is to be taken as medical or other health advice pertaining to any individual's specific health conditions. Move Daily is not engaged in rendering any medical services. Move Daily makes no guarantee regarding the accuracy, timeliness or relevance of any text, video or audio content. Any content provided is not a diagnosis, treatment plan or recommendation for a particular course of action regarding your health and it is not intended to provide specific medical advice. Do not delay in seeking the advice and diagnosis of a medical professional because of anything you may have read or interpreted from Move Daily Fitness content.  Consult your health care professional before participating in or acting on any recommendations found on Move Daily Fitness.  You agree, at your exposure, to indemnify and hold Move Daily Fitness and Tracy Steen harmless from any and all losses, liabilities and injuries, or damages resulting from and all claims, cause of action, suits, proceedings and demands against Move Daily Fitness and Tracy Steen, arising from or related to decisions or recommendations you make using Move Daily Fitness content. You agree that use of this information is at your own riskIf you love total body workouts, and are looking to increase muscle, this Total Body Split Calendar (follow along video) is for you! Grab yours here today and get started.  The Move Daily Membership is a paid monthly subscription for women, which gives you access to a huge amount of resources to help support you in reaching your health goals. Whether you're looking to lose fat, gain lean muscle, focus on your nutrition, give time to wellness or simply wish to dial in your overall health, we can support you in achieving your objectives. Join today! Shop Legion Supplements and use discount code: MoveDailyThis is an affiliate link.Support the showUse discount code PODCAST10 for a discount on your Move Daily Membership. Don't fade out women, level up!Thanks for moving daily with us in your fitness, wellness and nutrition! Be sure to follow us here:YouTubeInstagramFacebookTikTokSubscribe to my podcast! 

[20260522] Crónicas de San Borondón ‘Crónicas de San Borondón‘, el programa de La Radio Canaria sobre enigmas relacionados con la arqueología y civilizaciones antiguas, que se emite los viernes a las 22:00 horas, dedicará buena parte de su contenido a bucear en el lado oscuro de los aborígenes canarios. Contará para ello con la participación del periodista y divulgador Luis Socorro, especialista en periodismo sobre arqueología prehispánica en Canarias. «El sentido común, pero, sin duda alguna, la arqueología y sus disciplinas más próximas han revelado que la violencia estuvo muy presente, en cierto momento de la historia, entre los antiguos canarios», adelanta José Gregorio González, director y conductor de ‘Crónicas de San Borondón'. El hallazgo reciente de cráneos decapitados post mortem en la isla de La Palma será el punto de partida de la conversación que mantendrá José Gregorio González con el periodista Luis Socorro, una de las voces autorizadas en la divulgación periodística sobre arqueología y autor de ‘Amaziges de Canarias' y ‘Astrónomos del Pasado'. Mentes criminales La segunda aproximación a las oscuridades del ser humano vendrá de la mano de la experta en comportamiento no verbal Priscila González y del psicólogo y perfilador criminal Juan Enrique Soto. Ambos dialogarán en ‘Crónicas de San Borondón' sobre la mente criminal y el alcance social de ciertos crímenes que ocasionaron un fuerte impacto en la sociedad de su tiempo. Enanos y malditos Como cada semana, una nueva entrega de la sección ‘El Gabinete del Curioseante', con Ricardo Martín, que en esta ocasión pondrá el foco en los ‘golluts' y los ‘cagots', antiguos pobladores del Pirineo, enanos y considerados ‘malditos'. Martín hablará sobre cuánto de verdad y cuánto de mitología rodea la existencia de estos seres humanos apartados del contacto social. ‘Crónicas de San Borondón' avanzará, como cada semana en La Radio Canaria, novedades y agenda de actos relacionados con mitos, leyendas, fenómenos paranormales y arqueología.

Today's Poll Question at Smerconish.com: Genes or money — which shapes a child's brain more? Michael revisits the classic nature-versus-nurture debate, but with a modern twist. Prompted by new research from Washington University in St. Louis, he examines evidence suggesting that socioeconomic factors—including income, neighborhood conditions, stress, sleep, and screen time—may have a profound impact on measurable brain development in children. He also connects the findings to economist Raj Chetty's work on economic mobility and the power of cross-class friendships. Is money really the key factor, or is it a proxy for something larger: opportunity, connection, and social capital? Listen here, then vote, and be sure to rate, review and share this podcast! Hosted by Simplecast, an AdsWizz company. See https://pcm.adswizz.com for information about our collection and use of personal data for advertising.

Can genetics explain chronic gut issues, thyroid symptoms, inflammation, and why one person can “eat poorly” and feel fine while another does everything right and still struggles? What if your best diet depends on your genetic carb tolerance, plus things like caffeine and histamine sensitivity? On this episode of the She Talks Health Podcast, I sat down with Dr. Sam Shay to talk about how functional genetics can validate what you've probably felt in your body for years and give you a practical roadmap forward. We started things off with Dr. Shay's story of being really unwell as a child, and how that pushed him to seek out his own information about his health. As a kid, he struggled with things like years of crippling insomnia, violence in school, and developing a caffeine habit at only 6 years old. His desire to find answers about his health struggles led him to specialize in genetics and train other practitioners in this modality.Later, we got into the details of what our genetics really tell us about our health. We discuss that inflammation is a major driver of chronic illness, and that “bad genes” are often really an environmental mismatch with evolutionary tradeoffs. So if you're feeling as though you're chronically inflamed but are doing everything “right”, your genetics might be the missing piece to the puzzle here. Your genetics can even tell you about how well you digest carbs, and who does better with lower vs higher carb diets. If you've ever tried a diet that made you feel completely messed up but didn't know why, this could explain a lot for a lot of people. We also touched on genes related to caffeine-induced anxiety/depression, histamine sensitivity, and why Dr. Shay focuses on testing “drivers of disease” (like inflammation, free radicals/mitochondria, etc.) rather than disease markers themselves.Our genetics make up every part of us, but they're rarely considered when it comes to chronic and “unexplainable” health problems. If you've ever dealt with chronic inflammation, unexplained weight gain, strange food intolerances, or even mental health issues, but your labs are always “normal,” the answers just might be in your genetics. Disclaimer: This information is being provided to you for educational and informational purposes only. It is being provided to educate you about how to take care of your body and as a self-help tool for your own use so that you can reach your own health goals. It is not intended to treat or cure any specific illness and is not to replace the guidance provided by your own medical practitioner. If you are under the care of a healthcare professional or currently use prescription medications, you should discuss any dietary changes or potential dietary supplement use with your doctor, and should not discontinue any prescription medications without first consulting your doctor. This information is to be used at your own risk based on your own judgment. If you suspect you have a medical problem, we urge you to take appropriate action by seeking medical attention.In This Episode: [2:50] Dr. Shay's story that led him to genetics testing[8:45] What Dr. Shay learned about himself from his genetics test results[14:15] What's the benefit of having variations in how our bodies process different things?[19:45] Why a Mediterranean diet won't work for everyone[24:41] “The Finger Rule” for helping to decipher our test results[27:40] What happens when people start following The Finger Rule to change their diet[31:35] What can genetics testing can tell us beyond carb tolerance[36:03] Change your environment to match your genetics[36:35] The 7 drivers of disease that we can see in test results[40:10] 3 types of genetics-based weight gain and how to eliminate them[47:00] How to work with Dr. ShayFind more from Dr. Shay online:Website: https://drsamshay.com/https://fitgenesusa.com/Instagram: @drsamshayYouTube:https://www.youtube.com/@DrSamShayConnect with Sophie: Instagram: @shetalkshealthWebsite: shetalkshealth.comApply to work with us: www.shetalkshealth.com/callThe Mineral Reset (HTMA): https://shethrives.shetalkshealth.com/htma-packageMineral Mocktail (get your energy back now!: https://shetalkshealth.com/mineral-mocktail-guide/Stop guessing with your thyroid & Get Answers Now: https://ace.shetalkshealth.com/home-front

From peptides and protein, to sleep hygiene and vaccines, what actually helps you age well? Physician Eric Topol breaks down the science — and the myths — of longevity and anti-aging.TED Radio Hour+ listeners now get access to bonus episodes, with more ideas from TED speakers and deeper conversations with Manoush. By signing up for Plus, you directly support our work and public media, so all your episodes (like this one!) come to you without sponsor breaks. Learn more at plus.npr.org/ted.See pcm.adswizz.com for information about our collection and use of personal data for sponsorship and to manage your podcast sponsorship preferences.NPR Privacy Policy